Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.5252W HIGH $2.35
Volume
3.64 M
Value Traded
1.76 M
Short % Float
9.78%
-3.53%Week
-17.67%1 Month
-37.48%3 Month
-21.13%6 Month
-96.04%5 Year
-96.04%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
122.03 M
EPS (TTM)
-0.46
P/E Ratio
-
Ent. Value
43.94 M
Total Shares
224.23 M
Float Shares
221.23 M
Insiders
1.34%
Institutions
25.64%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
TNYA Catalyst Timeline
Dated clinical, regulatory and corporate events for Tenaya Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Tenaya Therapeutics, Inc.
316Total events
12Upcoming
40Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲RMATTN-401Designation
FDA grants RMAT designation to TN-401 for PKP2-associated ARVC
PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC)source ↗
▲Enrollment CompleteTN-201Trial
Enrollment completed in MyPEAK-1 trial to characterize dose response
MYBPC3-associated hypertrophic cardiomyopathysource ↗
▲Enrollment CompleteTN-401Trial
Enrollment completed in RIDGE-1 trial to characterize dose response
PKP2-associated arrhythmogenic right ventricular cardiomyopathysource ↗
◆Oral PresentationPresentation
Tenaya Therapeutics to present at Jefferies Global Healthcare Conference 2026
●Oral PresentationTN-201Presentation
Management webcast conference call to review MyPEAK-1 interim data
MYBPC3-associated hypertrophic cardiomyopathysource ↗
▲Topline ReadoutTN-201Clinical Data
Interim data from MyPEAK-1 showing improvements in cardiac remodeling and symptoms
MYBPC3-associated hypertrophic cardiomyopathysource ↗
▲EMA PrimeTN-201Ex-US Regulatory
TN-201 granted PRIME designation by EMA
MYBPC3-associated hypertrophic cardiomyopathysource ↗
▲FDA Feedback ReceivedTN-201FDA Meeting
TN-201 pediatric indication accepted into FDA's Rare Disease Evidence Principles process
MYBPC3-associated hypertrophic cardiomyopathy (pediatric biallelic)source ↗
◆Enrollment UpdateTN-201Trial
Continuing to enroll adults at 6E13 vg/kg dose in expansion cohort
MYBPC3-associated hypertrophic cardiomyopathysource ↗
▲Interim Efficacy DataTN-201Clinical Data
Positive interim data from MyPEAK-1 trial of TN-201
MYBPC3-associated hypertrophic cardiomyopathysource ↗
▲EMA PrimeTN-201Ex-US Regulatory
TN-201 received PRIME designation from EMA
MYBPC3-associated hypertrophic cardiomyopathysource ↗
▲FDA Feedback ReceivedTN-201FDA Meeting
TN-201 accepted into FDA's Rare Disease Evidence Principles process
MYBPC3-associated hypertrophic cardiomyopathysource ↗
●Manufacturing MilestoneCMC / Inspection
Lease termination for Genetic Medicines Manufacturing Center
◆Late-BreakerTN-401Presentation
Late-breaking oral presentation of new clinical data from RIDGE-1 trial of TN-401 at ASGCT 2026
PKP2-associated ARVCsource ↗
◆Timing GuidanceTN-401Presentation
Webcast conference call to discuss TN-401 data at ASGCT 2026
PKP2-associated ARVCsource ↗
◆Enrollment UpdateTN-401Trial
Two additional patients dosed in 6E13 vg/kg expansion cohort
PKP2-associated ARVCsource ↗
●Poster PresentationTN-501Presentation
Poster presentation on development of TN-501 gene editing therapy
PLN-R14del-associated dilated cardiomyopathysource ↗
◆Oral PresentationTN-401Presentation
One-Year Cohort 1 Data and Initial Cohort 2 Data from RIDGE-1 Phase 1b/2 Trial of TN-401 to be Presented at ASGCT 2026
PKP2-Associated ARVCsource ↗
●Poster PresentationPresentation
Poster presentation on parental perceptions of gene therapy for children with cardiomyopathies
Cardiomyopathy (pediatric)source ↗
▲Partnership / LicenseCorporate
Entered Research Collaboration with Alnylam to Identify and Validate Genetic Targets for Cardiovascular Conditions
▲Oral PresentationTN-401Presentation
RIDGE-1 interim data presented at ASGCT Annual Meeting
PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC)source ↗
▲EMA PrimeTN-401Ex-US Regulatory
TN-401 received PRIME designation from EMA
PKP2-associated arrhythmogenic right ventricular cardiomyopathysource ↗
▲Interim Efficacy DataTN-401Clinical Data
Interim RIDGE-1 data showed reduced PVC and NSVT rates
PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC)source ↗
◆Topline ReadoutTN-201Clinical Data
New Data from Both Cohorts of MyPEAK-1 Phase 1b/2 Trial of TN-201 Expected in Q2 2026
MYBPC3-Associated HCMsource ↗
▲Partnership / LicenseCorporate
Received $10 million upfront payment from Alnylam collaboration
▲Partnership / LicenseCorporate
Multi-target research collaboration with Alnylam Pharmaceuticals
Cardiovascular diseasesource ↗
◆Oral PresentationPresentation
Tenaya management to participate in fireside chat at Leerink Partners Global Healthcare Conference 2026
▲Poster PresentationTN-301Presentation
Poster presentation at MDA 2026: TN-301 improves muscle function and molecular pathology in mdx mice and corrects human DMD iPSC-cardiomyocyte phenotypes
Duchenne muscular dystrophysource ↗
▲Partnership / LicenseCorporate
Research collaboration with Alnylam to identify and validate novel genetic targets for cardiovascular disease
cardiovascular diseasessource ↗
▲Poster PresentationTN-301Presentation
Preclinical data for TN-301 in DMD model presented at MDA 2026 Congress
Duchenne muscular dystrophy (DMD)source ↗
▲DSMB ReviewTN-401Trial
DSMB review endorsed continued enrollment at either dose
PKP2-associated ARVCsource ↗
●Protocol AmendmentTN-201Trial
Protocol amendments implemented in alignment with FDA input
MYBPC3-associated HCMsource ↗
▲Enrollment UpdateTN-201Trial
Enrollment resumed in MyPEAK-1 after protocol amendments
MYBPC3-associated HCMsource ↗
▲Interim Efficacy DataTN-401Clinical Data
Positive interim data from RIDGE-1 trial of TN-401
PKP2-associated arrhythmogenic right ventricular cardiomyopathysource ↗
▲Enrollment CompleteTN-201Trial
Enrollment completed in MyPEAK-1 trial
MYBPC3-associated hypertrophic cardiomyopathysource ↗
▲Enrollment CompleteTN-401Trial
Enrollment completed in RIDGE-1 trial
PKP2-associated arrhythmogenic right ventricular cardiomyopathysource ↗
▼Equity OfferingCorporate
Pricing of underwritten public offering of 50,000,000 units at $1.20 per unit for gross proceeds of $60 million
▲Topline ReadoutTN-401Clinical Data
Positive interim data from Cohort 1 of RIDGE-1 trial of TN-401
PKP2-associated ARVCsource ↗
▲Enrollment CompleteTN-401Trial
Enrollment and dosing complete for Cohort 2 (6E13 vg/kg) of RIDGE-1
PKP2-associated ARVCsource ↗
●Oral PresentationTN-401Presentation
Webcast conference call to discuss TN-401 data
PKP2-associated ARVCsource ↗
▲Clinical Hold LiftedTN-201IND
FDA lifts clinical hold on MyPEAK-1 trial of TN-201
MYBPC3-associated hypertrophic cardiomyopathysource ↗
Past FDA Catalysts and PDUFA Decisions
How TNYA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-15 | TN-401 | Phase 1b/2 interim results | Phase 1b/2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D35 / 100
Pipeline Score
$3M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Top 55%
Micro Cap(rank 362 of 658)
Percentile Rank
Tenaya Therapeutics, Inc. faces pipeline headwinds (35/100), with $11M risk-adjusted pipeline value, with 2 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TN-401 Gene therapyNCT06228924 | Arrhythmogenic Right Ventricular Cardiomyopathy | Phase 1 | RECRUITING | 15 | Oct 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every TNYA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| TN-201 Fast TrackOrphanRare Pediatric | MYBPC3-associated hypertrophic cardiomyopathy (HCM) | Phase 1b/2 | 2026-06-03 | All evaluable patients experienced enhancements in clinical measures; Cohort 1 patients sustained benefits as far out as two years; Cohort 2 patients showed greater symptom relief and improved cardiac function at earlier timepoint; Improvements in multiple clinical parameters of disease including echocardiographic measures of hypertrophy; Three patients had improvements in exercise capacity by at least one measure; Cardiac troponin improved or remained stable in five of six patients; NT-pro BNP improved in three patients; All six evaluable patients achieved reductions in left ventricular mass index (LVMI); Five of six demonstrated reductions in one or more measures of wall thicknessRead More | Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in SymptomsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Ali FarazDirector, Officer (Chief Executive Officer) | Sell | -5,837 434,177 held | $0.71 | 08/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TNYA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Casdin Capital, LLC | 0 % | 267.00 K | 361.97 K |
TNYA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-04-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TNYA ranks across every disease it competes in
Competitive Position is a premium feature
See how TNYA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTNYA News
TNYA▲ +8.3%on this news
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
Tenaya Therapeutics has received RMAT designation from the FDA for TN-401, a gene therapy aimed at treating PKP2-associated arrhythmogenic right ventricular cardiomyopathy. This designation is supported by positive interim results from the RIDGE-1 Phase 1b/2 clinical trial, which showed significant reductions in arrhythmia rates. The company anticipates sharing further data and updates on regulatory discussions in Q4 2026.
Read more →TNYATenaya Therapeutics to Participate in Upcoming September Investor Conferences
Tenaya Therapeutics, a clinical-stage biotechnology firm, will host investor meetings at two upcoming conferences: the H.C. Wainwright 28th Annual Global Investment Conference on September 14 and the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. A fireside chat from the H.C. Wainwright conference will be available on demand starting September 11. Tenaya's pipeline includes innovative gene therapies targeting heart disease.
Read more →TNYA▼ -7.5%on this news
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Tenaya Therapeutics reported positive interim data from its TN-201 and TN-401 clinical trials during Q2 2026. The company received a $10 million upfront payment from Alnylam, extending its cash runway through Q3 2027. Additionally, Tenaya is advancing TN-301 towards a Phase 2 trial start in the second half of 2027, while managing a net loss of $43.4 million for the quarter.
Read more →TNYA▲ +5.8%on this newsshared move
Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
Tenaya Therapeutics will participate in the Canaccord Genuity 46th Annual Growth Conference on August 11-12, 2026, in Boston. The company's CFO, Eric Hyllengren, will host a fireside chat during the event. This engagement aims to connect with investors and showcase Tenaya's commitment to developing therapies for heart disease.
Read more →TNYATenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Tenaya Therapeutics has announced the grant of stock options totaling 1,650,000 shares to its new CFO and 187,200 shares to two new non-executive employees. This action is part of their 2024 Inducement Equity Incentive Plan and aligns with NASDAQ Listing Rule 5635(c)(4). The stock options have a ten-year term and will vest over four years, reflecting the company's commitment to attract talent as it develops therapies for heart disease.
Read more →TNYATenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
Tenaya Therapeutics has appointed Eric Hyllengren as Chief Financial Officer, effective July 13, 2026. Hyllengren, who has over two decades of experience in biotechnology finance, will oversee financial strategy and corporate development. His appointment comes as Tenaya prepares for pivotal clinical trials and aims to advance its genetic medicines for heart disease. Additionally, Hiro Higa will retire but remain as a consultant during the transition.
Read more →TNYATenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms
Tenaya Therapeutics reported interim data from its MyPEAK-1 Phase 1b/2 trial of TN-201, showing significant improvements in patients with MYBPC3-associated hypertrophic cardiomyopathy (HCM). All evaluable patients experienced enhancements in clinical measures, with notable durability in responses. The higher dose cohort exhibited greater symptom relief sooner. TN-201 has been granted PRIME designation by the EMA.
Read more →TNYATenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
Tenaya Therapeutics will announce new interim data from its MyPEAK-1 Phase 1b/2 trial of TN-201, a gene therapy for adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM), on June 3, 2026. The company aims to address the underlying genetic causes of HCM, a severe condition affecting many patients. The webcast will provide insights into the trial's findings.
Read more →TNYA▲ +8.8%on this newsshared move
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026
Tenaya Therapeutics will present at the Jefferies Global Healthcare Conference from June 2-4, 2026. CEO Faraz Ali is scheduled to deliver a presentation on June 4 at 3:10 p.m. ET. The event will highlight Tenaya's commitment to developing therapies for heart disease, including their clinical-stage candidates.
Read more →TNYA▼ -8.3%on this news
Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
Tenaya Therapeutics reported positive interim data from its RIDGE-1 Phase 1b/2 clinical trial of TN-401 gene therapy for PKP2-associated ARVC. All patients showed significant reductions in premature ventricular contractions, with a mean decrease of 64%. The therapy was well tolerated, and biopsies indicated effective transduction in heart muscle cells. The European Medicines Agency granted PRIME designation to TN-401, highlighting its potential to address unmet medical needs.
Read more →TNYA▲ +7.4%on this news· ran to +27% by day 1
Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Tenaya Therapeutics reported its first quarter 2026 financial results, highlighting upcoming clinical milestones for its gene therapies TN-201 and TN-401. The company also presented new preclinical data for TN-301, a small molecule candidate for various cardiac conditions. Additionally, a collaboration with Alnylam aims to identify genetic targets for cardiovascular diseases.
Read more →TNYATenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026
Tenaya Therapeutics announced that new clinical data from the RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy will be presented at the ASGCT Annual Meeting 2026. The therapy targets adults with PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). The presentation will include safety and efficacy data from two dose cohorts, showcasing the potential of TN-401 in treating this condition.
Read more →TNYATenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Tenaya Therapeutics has announced its fourth quarter and full year 2025 financial results, highlighting promising advancements in its gene therapy programs, TN-201 for hypertrophic cardiomyopathy and TN-401 for arrhythmogenic right ventricular cardiomyopathy. The company reported successful safety and efficacy results from recent clinical trials, along with plans for additional updates and regulatory alignment in 2026. Additionally, Tenaya entered a research collaboration with Alnylam Pharmaceuticals, aiming to explore new genetic targets for cardiovascular disease treatments. The company's financial stability is strengthened by a recent funding round, enabling sustained development efforts going into 2027.
Read more →TNYA▲ +7.8%on this newsshared move
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy
Tenaya Therapeutics presented promising preclinical data for TN-301, a selective HDAC6 inhibitor, at the MDA 2026 conference. The data showed TN-301's potential to improve muscle function and address cardiomyopathy in Duchenne muscular dystrophy (DMD). The drug outperformed the approved agent givinostat in animal models, leading Tenaya to plan for Phase 2 clinical development.
Read more →TNYA▲ +40.9%on this news· ran to +54% by day 3shared move
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
Tenaya Therapeutics has announced a research collaboration with Alnylam Pharmaceuticals to identify and validate novel genetic targets for cardiovascular disease therapies. Tenaya will receive up to $10 million upfront, along with potential milestone payments totaling $1.13 billion. This partnership aims to leverage both companies' strengths to develop transformative treatments for heart disease.
Read more →TNYATenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026
Tenaya Therapeutics will participate in the Leerink Partners Global Healthcare Conference from March 9-11, 2026, in Miami, Florida. CEO Faraz Ali is scheduled for a fireside chat on March 9 at 1:00 pm ET. The event will be accessible via live webcast, with an archived replay available for 30 days post-conference.
Read more →TNYATenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones
Tenaya Therapeutics has outlined its strategic priorities for 2026, focusing on advancing its gene therapy programs TN-201 and TN-401. The company aims to build on positive interim results from 2025, with key data readouts expected in the first half of 2026. Additionally, Tenaya raised $60 million to support its operations through mid-2027.
Read more →TNYA▼ -37.5%on this news· ran to -51% by day 3
Tenaya Therapeutics Announces Pricing of Public Offering
Tenaya Therapeutics has announced the pricing of its public offering, aiming to raise $60 million through the sale of 50 million units. Each unit consists of a share of common stock and a warrant for additional shares. The proceeds will support the development of clinical candidates TN-201 and TN-401, with the offering expected to close on December 15, 2025.
Read more →TNYA▼ -37.5%on this news· ran to -51% by day 3shared move
Tenaya Therapeutics Announces Proposed Public Offering
Tenaya Therapeutics announced its intention to conduct a public offering of units consisting of common stock and warrants. The offering is subject to market conditions and may include pre-funded units. Leerink Partners and Piper Sandler are acting as joint bookrunning managers. The company focuses on developing therapies for heart disease, with several clinical-stage candidates in its pipeline.
Read more →About Tenaya Therapeutics, Inc.
Headquarters171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE PLUS
Trade the next TNYA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime